Glafabra Granted Orphan Drug Designation ODD detail Rogue Funds Signs Commitment Lead investor detail Glafabra Q3 Update Glafabra' progress towards partnering Comparison of LVV to AAV and Abs see how Abs predict LVV future Stem Cell Therapy for Fabry Disease understand the therapeutic effect of cell therapy Q2 Update 2025 Glafabra's Progress Towards Repeating Fabry Trials in USA Metabolic Enzyme Disorders Explore the diversity of metabolic enzyme disorders Options Agreement on Improved Lentivector Announcement of signed agreement Partnership with University of Utah Health Announcement of signed agreement Glafabra Welcomes Elizabeth Wagner to Advisory Board View press release New Fabry disease therapy shows 130x increase in effectiveness. Details on effectiveness
